1. Influence of Unrecognized Molecular Heterogeneity on Randomized Clinical Trials
2. Fukuoka M, Yano S, Giaccone G, et al: Final results from a phase II trial of ZD1839 (’Iressa’) for patients with advanced non-small-cell lung cancer (IDEAL 1). Proc Am Soc Clin Oncol 21: 298a,2002 (abstr 1188)
3. Kris MG, Natale RB, Herbst RS, et al: A phase II trial of ZD1839 (’Iressa’) in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (IDEAL 2). Proc Am Soc Clin Oncol 21: 292a,2002 (abstr 1166)
4. Ruckdeschel JC, Simon G, Antonia S, et al: ZD1839 (’Iressa’) as a single agent for the treatment of metastatic non-small-cell lung cancer. Proc Am Soc Clin Oncol 21: 318a,2002 (abstr 1269)